^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    OX40 ligand inhibitor

    Related drugs:
    5d
    Local Promoter Methylation Disorder algorithm reveals bidirectional epigenetic disruption in DNMT3A-mutated AML and predicts azacitidine treatment response. (PubMed, Front Oncol)
    The LPMD algorithm effectively captured DNMT3A mutation-associated epigenetic instability (Cohen's d = 0.8, p < 0.001), with the strongest effects observed in the 5'UTR-Exon1 region (d = 0.74) and a gradient pattern from CpG islands to shores (d: 0.59→0.54→0.43). The 5-DMDR panel offers a practical tool for azacitidine response prediction, while dynamic LPMD monitoring provides a potential biomarker for therapeutic guidance. These findings establish methylation disorder as a clinically actionable dimension of epigenetic dysregulation in myeloid malignancies.
    Journal
    |
    DNMT3A (DNA methyltransferase 1)
    |
    azacitidine
    10d
    Mainsail: A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa (clinicaltrials.gov)
    P2, N=115, Recruiting, Navigator Medicines, Inc.
    New P2 trial
    11d
    CHROMA CD: A study to investigate efficacy and safety of brivekimig in participants with Crohns disease (clinicaltrials.gov)
    P2, N=99, Recruiting, Sanofi
    Trial initiation date
    14d
    An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic Dermatitis (clinicaltrials.gov)
    P1, N=86, Active, not recruiting, Apogee Therapeutics, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Dupixent (dupilumab)
    14d
    NAV-240-201: A study to assess NAV-240 in adult participants with Hidradenitis Suppurativa (2025-523557-33-00)
    P1/2, N=40, Not yet recruiting, Navigator Medicines Inc.
    New P1/2 trial
    15d
    A First-in-Human Phase 1 Single-Ascending Dose Study of ABCL575 in Healthy Participants (clinicaltrials.gov)
    P1, N=40, Recruiting, AbCellera Biologics Inc. | Trial completion date: Nov 2026 --> Apr 2027 | Trial primary completion date: Nov 2026 --> Apr 2027
    Trial completion date • Trial primary completion date • First-in-human
    18d
    A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2) (clinicaltrials.gov)
    P3, N=589, Completed, Sanofi | Active, not recruiting --> Completed
    Trial completion
    29d
    COLOR UC: A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis (clinicaltrials.gov)
    P2, N=99, Recruiting, Sanofi
    Trial initiation date
    1m
    A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease (clinicaltrials.gov)
    P2, N=229, Active, not recruiting, Sanofi | Recruiting --> Active, not recruiting
    Enrollment closed
    1m
    DRI17963: A Phase 2a/b study of the efficacy and safety of subcutaneous amlitelimab in adults with non-responsive celiac disease (2024-511213-38-00)
    P1/2, N=374, Active, not recruiting, Sanofi-Aventis Recherche & Developpement | Recruiting --> Active, not recruiting
    Enrollment closed
    2ms
    DRI19220: Brivekimig for the treatment of moderate to severe hidradenitis suppurativa (2025-522333-61-00)
    P1/2, N=132, Recruiting, Sanofi-Aventis Recherche & Developpement
    New P1/2 trial
    2ms
    T1D OBTAIN: Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule (clinicaltrials.gov)
    P2, N=84, Active, not recruiting, Sanofi | Recruiting --> Active, not recruiting | Trial completion date: Sep 2028 --> Apr 2027 | Trial primary completion date: Aug 2027 --> Apr 2027
    Enrollment closed • Trial completion date • Trial primary completion date